THE BioMed Statistics

Total Valuation

THE BioMed has a market cap or net worth of KRW 46.35 billion. The enterprise value is 67.07 billion.

Market Cap	46.35B
Enterprise Value	67.07B

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	n/a

Share Statistics

THE BioMed has 8.38 million shares outstanding. The number of shares has increased by 51.26% in one year.

Current Share Class	5.15M
Shares Outstanding	8.38M
Shares Change (YoY)	+51.26%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	5.23%
Owned by Institutions (%)	38.59%
Float	3.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.09
PB Ratio	2.00
P/TBV Ratio	2.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.42
EV / Sales	14.60
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.90

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 0.91.

Current Ratio	0.96
Quick Ratio	0.12
Debt / Equity	0.91
Debt / EBITDA	n/a
Debt / FCF	-1.22
Interest Coverage	-12.46

Financial Efficiency

Return on equity (ROE) is -91.78% and return on invested capital (ROIC) is -27.36%.

Return on Equity (ROE)	-91.78%
Return on Assets (ROA)	-22.96%
Return on Invested Capital (ROIC)	-27.36%
Return on Capital Employed (ROCE)	-49.85%
Revenue Per Employee	91.85M
Profits Per Employee	-554.26M
Employee Count	50
Asset Turnover	0.09
Inventory Turnover	0.87

Taxes

Income Tax	-1.23B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -69.09% in the last 52 weeks. The beta is 0.24, so THE BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.24
52-Week Price Change	-69.09%
50-Day Moving Average	5,650.60
200-Day Moving Average	10,211.88
Relative Strength Index (RSI)	46.11
Average Volume (20 Days)	49,584

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, THE BioMed had revenue of KRW 4.59 billion and -27.71 billion in losses. Loss per share was -6,082.23.

Revenue	4.59B
Gross Profit	-3.58B
Operating Income	-18.58B
Pretax Income	-26.19B
Net Income	-27.71B
EBITDA	-16.72B
EBIT	-18.58B
Loss Per Share	-6,082.23

Full Income Statement

Balance Sheet

The company has 301.04 million in cash and 21.02 billion in debt, giving a net cash position of -20.72 billion or -2,471.31 per share.

Cash & Cash Equivalents	301.04M
Total Debt	21.02B
Net Cash	-20.72B
Net Cash Per Share	-2,471.31
Equity (Book Value)	23.22B
Book Value Per Share	4,509.23
Working Capital	-574.97M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -7.84 billion and capital expenditures -9.37 billion, giving a free cash flow of -17.21 billion.

Operating Cash Flow	-7.84B
Capital Expenditures	-9.37B
Free Cash Flow	-17.21B
FCF Per Share	-2,052.95

Full Cash Flow Statement

Margins

Gross Margin	-77.86%
Operating Margin	-404.51%
Pretax Margin	-570.20%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

THE BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-51.26%
Shareholder Yield	-51.26%
Earnings Yield	-59.78%
FCF Yield	-37.12%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on April 14, 2025. It was a reverse split with a ratio of 0.1.

Last Split Date	Apr 14, 2025
Split Type	Reverse
Split Ratio	0.1

Scores

THE BioMed has an Altman Z-Score of -4.32 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.32
Piotroski F-Score	2